Cardiac Arrhythmias Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major cardiac arrhythmias markets reached a value of US$ 4.9 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 8.0 Billion by 2034, exhibiting a growth rate (CAGR) of 4.57% during 2024-2034.
The cardiac arrhythmias market has been comprehensively analyzed in IMARC's new report titled "Cardiac Arrhythmias Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cardiac arrhythmias refer to a medical disorder in which there are abnormal electrical impulses in the heart that disrupt its normal rhythm. In this condition, the heart may beat too fast (tachycardia), too slow (bradycardia), or irregularly. These abnormal rhythms can occur in different areas of the heart, affecting the atria (upper chambers) or ventricles (lower chambers). Individuals suffering from the ailment may experience a fluttering in the chest, shortness of breath, anxiety, fatigue, lightheadedness, dizziness, excessive sweating, fainting episodes, chest pain, palpitations, etc. The diagnosis of cardiac arrhythmias typically involves a thorough medical history review, clinical assessment, and physical examination. A blood workup to evaluate the electrolyte levels or genetic mutations associated with the disease is also recommended for patients. The healthcare provider may perform several diagnostic procedures, such as an electrocardiogram, Holter monitoring, stress tests, an echocardiogram, electrophysiological studies, etc., to determine an irregular heart rhythm. Furthermore, a computed tomography scan and cardiac magnetic resonance imaging are utilized to provide detailed pictures of the heart and identify the exact cause of underlying symptoms.
The rising prevalence of abnormalities in the heart's structure, such as heart valve problems or scar tissue, which can disrupt the normal electrical pathways, is primarily driving the cardiac arrhythmias market. In addition to this, the increasing incidences of various associated risk factors, including high blood pressure, electrolyte imbalance, sleep apnea, excessive consumption of alcohol, obesity, etc., are also bolstering the market growth. Moreover, the widespread adoption of beta-blockers, such as atenolol, bisoprolol, metoprolol, etc., to reduce cardiac contractility and manage disease symptoms is acting as another significant growth-inducing factor. Apart from this, the inflating application of subcutaneous implantable cardioverter-defibrillators, which are implanted beneath the skin to monitor and deliver electrical therapy to patients, is further propelling the market growth. Additionally, the escalating demand for vagal nerve stimulation techniques, since they can decrease the duration and inducibility of arrhythmias by enhancing parasympathetic activity, is creating a positive outlook for the market. Besides this, the emerging popularity of cardiac resynchronization therapy that helps to optimize the pumping action of the heart, thereby leading to improved blood flow and increased cardiac output, is expected to drive the cardiac arrhythmias market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the cardiac arrhythmias market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cardiac arrhythmias and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cardiac arrhythmias market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the cardiac arrhythmias market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the cardiac arrhythmias market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current cardiac arrhythmias marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
Late-Stage Pipeline Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the cardiac arrhythmias market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the cardiac arrhythmias market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the cardiac arrhythmias market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of cardiac arrhythmias across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of cardiac arrhythmias by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of cardiac arrhythmias by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with cardiac arrhythmias across the seven major markets?
What is the size of the cardiac arrhythmias patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of cardiac arrhythmias?
What will be the growth rate of patients across the seven major markets?
Cardiac Arrhythmias: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for cardiac arrhythmias drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cardiac arrhythmias market?
What are the key regulatory events related to the cardiac arrhythmias market?
What is the structure of clinical trial landscape by status related to the cardiac arrhythmias market?
What is the structure of clinical trial landscape by phase related to the cardiac arrhythmias market?
What is the structure of clinical trial landscape by route of administration related to the cardiac arrhythmias market?
The cardiac arrhythmias market has been comprehensively analyzed in IMARC's new report titled "Cardiac Arrhythmias Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cardiac arrhythmias refer to a medical disorder in which there are abnormal electrical impulses in the heart that disrupt its normal rhythm. In this condition, the heart may beat too fast (tachycardia), too slow (bradycardia), or irregularly. These abnormal rhythms can occur in different areas of the heart, affecting the atria (upper chambers) or ventricles (lower chambers). Individuals suffering from the ailment may experience a fluttering in the chest, shortness of breath, anxiety, fatigue, lightheadedness, dizziness, excessive sweating, fainting episodes, chest pain, palpitations, etc. The diagnosis of cardiac arrhythmias typically involves a thorough medical history review, clinical assessment, and physical examination. A blood workup to evaluate the electrolyte levels or genetic mutations associated with the disease is also recommended for patients. The healthcare provider may perform several diagnostic procedures, such as an electrocardiogram, Holter monitoring, stress tests, an echocardiogram, electrophysiological studies, etc., to determine an irregular heart rhythm. Furthermore, a computed tomography scan and cardiac magnetic resonance imaging are utilized to provide detailed pictures of the heart and identify the exact cause of underlying symptoms.
The rising prevalence of abnormalities in the heart's structure, such as heart valve problems or scar tissue, which can disrupt the normal electrical pathways, is primarily driving the cardiac arrhythmias market. In addition to this, the increasing incidences of various associated risk factors, including high blood pressure, electrolyte imbalance, sleep apnea, excessive consumption of alcohol, obesity, etc., are also bolstering the market growth. Moreover, the widespread adoption of beta-blockers, such as atenolol, bisoprolol, metoprolol, etc., to reduce cardiac contractility and manage disease symptoms is acting as another significant growth-inducing factor. Apart from this, the inflating application of subcutaneous implantable cardioverter-defibrillators, which are implanted beneath the skin to monitor and deliver electrical therapy to patients, is further propelling the market growth. Additionally, the escalating demand for vagal nerve stimulation techniques, since they can decrease the duration and inducibility of arrhythmias by enhancing parasympathetic activity, is creating a positive outlook for the market. Besides this, the emerging popularity of cardiac resynchronization therapy that helps to optimize the pumping action of the heart, thereby leading to improved blood flow and increased cardiac output, is expected to drive the cardiac arrhythmias market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the cardiac arrhythmias market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cardiac arrhythmias and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cardiac arrhythmias market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the cardiac arrhythmias market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the cardiac arrhythmias market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current cardiac arrhythmias marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
Late-Stage Pipeline Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the cardiac arrhythmias market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the cardiac arrhythmias market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the cardiac arrhythmias market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of cardiac arrhythmias across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of cardiac arrhythmias by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of cardiac arrhythmias by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with cardiac arrhythmias across the seven major markets?
What is the size of the cardiac arrhythmias patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of cardiac arrhythmias?
What will be the growth rate of patients across the seven major markets?
Cardiac Arrhythmias: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for cardiac arrhythmias drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cardiac arrhythmias market?
What are the key regulatory events related to the cardiac arrhythmias market?
What is the structure of clinical trial landscape by status related to the cardiac arrhythmias market?
What is the structure of clinical trial landscape by phase related to the cardiac arrhythmias market?
What is the structure of clinical trial landscape by route of administration related to the cardiac arrhythmias market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CARDIAC ARRHYTHMIAS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CARDIAC ARRHYTHMIAS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CARDIAC ARRHYTHMIAS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 CARDIAC ARRHYTHMIAS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CARDIAC ARRHYTHMIAS - UNMET NEEDS
10 CARDIAC ARRHYTHMIAS - KEY ENDPOINTS OF TREATMENT
11 CARDIAC ARRHYTHMIAS - MARKETED PRODUCTS
11.1 List of Cardiac Arrhythmias Marketed Drugs Across the Top 7 Markets
11.1.1 Multaq (Dronedarone) - Sanofi
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Betapace AF (Sotalol) - Berlex Laboratories
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Nexterone (Amiodarone) - Baxter
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Savaysa (Edoxaban) - Daiichi Sankyo Company
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CARDIAC ARRHYTHMIAS - PIPELINE DRUGS
12.1 List of Cardiac Arrhythmias Pipeline Drugs Across the Top 7 Markets
12.1.1 HSY244 - Novartis Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 S48168 - Armgo Pharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 HBI-3000 - HUYA Bioscience International
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 AP 30663 - Acesion Pharma
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Etripamil - Milestone Pharmaceuticals
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CARDIAC ARRHYTHMIAS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CARDIAC ARRHYTHMIAS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CARDIAC ARRHYTHMIAS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Cardiac Arrhythmias - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Cardiac Arrhythmias - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Cardiac Arrhythmias - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Cardiac Arrhythmias - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Cardiac Arrhythmias - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Cardiac Arrhythmias - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Cardiac Arrhythmias - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Cardiac Arrhythmias - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Cardiac Arrhythmias - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Cardiac Arrhythmias - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Cardiac Arrhythmias - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Cardiac Arrhythmias - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Cardiac Arrhythmias - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Cardiac Arrhythmias - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Cardiac Arrhythmias - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Cardiac Arrhythmias - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Cardiac Arrhythmias - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Cardiac Arrhythmias - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Cardiac Arrhythmias - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Cardiac Arrhythmias - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Cardiac Arrhythmias - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Cardiac Arrhythmias - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Cardiac Arrhythmias - Access and Reimbursement Overview
16 CARDIAC ARRHYTHMIAS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CARDIAC ARRHYTHMIAS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CARDIAC ARRHYTHMIAS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CARDIAC ARRHYTHMIAS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CARDIAC ARRHYTHMIAS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CARDIAC ARRHYTHMIAS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 CARDIAC ARRHYTHMIAS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CARDIAC ARRHYTHMIAS - UNMET NEEDS
10 CARDIAC ARRHYTHMIAS - KEY ENDPOINTS OF TREATMENT
11 CARDIAC ARRHYTHMIAS - MARKETED PRODUCTS
11.1 List of Cardiac Arrhythmias Marketed Drugs Across the Top 7 Markets
11.1.1 Multaq (Dronedarone) - Sanofi
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Betapace AF (Sotalol) - Berlex Laboratories
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Nexterone (Amiodarone) - Baxter
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Savaysa (Edoxaban) - Daiichi Sankyo Company
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CARDIAC ARRHYTHMIAS - PIPELINE DRUGS
12.1 List of Cardiac Arrhythmias Pipeline Drugs Across the Top 7 Markets
12.1.1 HSY244 - Novartis Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 S48168 - Armgo Pharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 HBI-3000 - HUYA Bioscience International
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 AP 30663 - Acesion Pharma
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Etripamil - Milestone Pharmaceuticals
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CARDIAC ARRHYTHMIAS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CARDIAC ARRHYTHMIAS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CARDIAC ARRHYTHMIAS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Cardiac Arrhythmias - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Cardiac Arrhythmias - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Cardiac Arrhythmias - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Cardiac Arrhythmias - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Cardiac Arrhythmias - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Cardiac Arrhythmias - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Cardiac Arrhythmias - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Cardiac Arrhythmias - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Cardiac Arrhythmias - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Cardiac Arrhythmias - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Cardiac Arrhythmias - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Cardiac Arrhythmias - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Cardiac Arrhythmias - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Cardiac Arrhythmias - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Cardiac Arrhythmias - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Cardiac Arrhythmias - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Cardiac Arrhythmias - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Cardiac Arrhythmias - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Cardiac Arrhythmias - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Cardiac Arrhythmias - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Cardiac Arrhythmias - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Cardiac Arrhythmias - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Cardiac Arrhythmias - Access and Reimbursement Overview
16 CARDIAC ARRHYTHMIAS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CARDIAC ARRHYTHMIAS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CARDIAC ARRHYTHMIAS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
